Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 50.73

-5.2%

Nov 19 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (9671)	12/5/2003 5:38:41 PM
From: Biomaven	Read Replies (1) of 52153

respond to new (or imminent) viral strains much more quickly That might give them a significant advantage. Right now there is over a 6 month lag after the strain is known to when the drug is available. (The WHO makes the strain recommendations at the end of February). Baxter apparently also has a cell-based (vero, not human) flu vaccine that I think is approved in Europe: intercell.com So they seem to be well in the lead. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next